Enanta Pharmaceuticals Announces the Election of Bruce L.A. Carter, Ph.D. as Non-Executive Chairman of the Board of Directors
December 14 2015 - 8:00AM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced the Board of Directors has elected Bruce L.A. Carter,
Ph.D. as non-executive Chairman of the Board. Dr. Carter has been
an independent director of Enanta since November 2013. He currently
serves as the Chair of the Compensation Committee and is a member
of the Nominating and Corporate Governance Committee.
“Since his appointment in 2013, Bruce has used his extensive
industry experience to provide great judgment and strong leadership
to the Enanta Board. We look forward to his continuing leadership
in his new role at Enanta,” stated Jay R. Luly, Ph.D., President
and Chief Executive Officer.
Dr. Carter has extensive experience in the pharmaceutical and
biotechnology industries, having served as Corporate Executive Vice
President and Chief Scientific Officer of Novo Nordisk and as an
executive in research at ZymoGenetics and G.D.Searle. Dr. Carter
was the President and CEO of ZymoGenetics until 2009, and served
most recently as the Executive Chairman of Immune Design Corp.
until 2011. He has served as a director of several biotechnology
companies, including as non-executive Chairman of the Board of
ZymoGenetics when it was sold to Bristol-Myers Squibb in 2010, and
currently serves as a director of Dr. Reddy’s Laboratories and
Xencor, Inc. Dr. Carter is also an Affiliate Professor, Department
of Biochemistry at the University of Washington, Seattle,
Washington and serves as Board Chair of the Infectious Disease
Research Institute in Seattle, Washington and is on the Board of
Directors of the TB Alliance.
Dr. Carter received a B.Sc. with Honors in Botany from the
University of Nottingham, England, and a Ph.D. in Microbiology from
Queen Elizabeth College, University of London.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta has developed novel protease and NS5A inhibitors that are
members of the direct-acting-antiviral (DAA) inhibitor classes
designed for use against the hepatitis C virus (HCV). Enanta’s
protease inhibitors partnered with AbbVie include paritaprevir,
which is contained in AbbVie’s marketed DAA regimens for HCV, and
ABT-493, Enanta’s next-generation protease inhibitor which AbbVie
is developing in phase 3 studies in combination with ABT-530,
AbbVie’s next-generation NS5A inhibitor. Enanta also has discovered
EDP-494, a host-targeted antiviral (HTA) inhibitor for HCV targeted
against cyclophilin, which Enanta plans to study in a phase 1
clinical trial in the first quarter of 2016. In addition, Enanta
has a preclinical program in non-alcoholic steatohepatitis, or
NASH, which is a condition that results in liver inflammation and
liver damage caused by a buildup of fat in the liver.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151214005108/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.comorMedia ContactMacDougall
Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024